- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
The South Korean company, Celltrion has developed a neutralising antibody cocktail with Regdanvimab (CT-P59) which will be effective against the variant strains of COVID-19.
This has been independently assessed and confirmed by The Korea Disease Control and Prevention Agency (KDCA). Officials confirmed that CT-P59 successfully neutralises the SARS-CoV-2 variants first identified in the UK (B.1.1.7) in addition to the previously identified six variant genome mutations of SARS-CoV-2 (variants S·L·V·G·GH·GR). They also added that cocktail therapy of CT-P59 with another monoclonal antibody candidate demonstrated neutralising capability against the UK variant (B.1.1.7) and the South African variant (B.1.351).
Countering Misinformation & Disinformation: Practical Training for Organizations
Practical skills to detect, verify, and respond across an evolving information landscape
Additional data provided by
English
Japanese
